Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study-Reference-Cited by-同舟云学术

Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study

Published:2014-05-03 Issue:8 Volume:261 Page:1469-1476
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Jongen Peter Joseph, ,Lehnick Dirk,Koeman Jan,Frequin Stephan,Heersema Dorothea,Kornips Bert,Schyns-Soeterboek Angelique,Visser Leo H.,Schiphof Paul,Valkenburg Anton,Hiel Johan

Publisher

Springer Science and Business Media LLC

Subject

Clinical Neurology,Neurology

Link

http://link.springer.com/article/10.1007/s00415-014-7363-2/fulltext.html

Reference21 articles.

1. Wolinsky JS (2006) The use of glatiramer acetate in the treatment of multiple sclerosis. Adv Neurol 98:273–292

2. Johnson KP, Due DL (2009) Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res 9(3):205–214. doi: 10.1586/erp.09.20

3. Metz LM, Patten SB, Archibald CJ, Bakker JI, Harris CJ, Patry DG, Bell RB, Yeung M, Murphy WF, Stoian CA, Billesberger K, Tillotson L, Peters S, McGowan D (2004) The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry 75(7):1045–1047

4. Ziemssen T, Hoffman J, Apfel R, Kern S (2008) Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health Qual Life Outcomes 6:67. doi: 10.1186/1477-7525-6-67

5. Jongen PJ, Lehnick D, Sanders E, Seeldrayers P, Fredrikson S, Andersson M, Speck J (2010) Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health Qual Life Outcomes 8:133. doi: 10.1186/1477-7525-8-133

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic literature review of the measurement of patient-reported fatigue in studies of disease modifying therapies for multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-11

2. Trajectories of self-reported fatigue following initiation of multiple sclerosis disease-modifying therapy;Journal of Neurology, Neurosurgery & Psychiatry;2024-05-14

3. Impact of Disease Modifying Therapy on MS-Related Fatigue: A Narrative Review;Brain Sciences;2023-12-20

4. Symptomatic Drug Treatment of Fatigue;Fatigue in Multiple Sclerosis;2023

5. Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practice;Neurodegenerative Disease Management;2022-12